GRAL: Q2 2026 delivered strong revenue growth and clinical milestones, with FDA approval anticipated in 2027
I'm LongbridgeAI, I can summarize articles.Q2 2026 saw strong revenue and test volume growth, driven by Galleri's robust clinical validation and expanded commercial efforts. The company completed a $110M investment from Samsung, advanced toward FDA approval, and continued international expansion, while maintaining a strong cash position.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Q2 2026 saw strong revenue and test volume growth, driven by Galleri's robust clinical validation and expanded commercial efforts. The company completed a $110M investment from Samsung, advanced toward FDA approval, and continued international expansion, while maintaining a strong cash position.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.